Congress Materials – German Society for Hematology and Medical Oncology (DGHO 2024)
2024 German Society for Hematology and Medical Oncology | Oct 11-14 | Basel, Germany
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Amivantamab Plus Chemotherapy vs Chemotherapy as First-Line Treatment in EGFR Exon 20 Insertion-mutated Advanced NSCLC: Analysis of Post-Progression Endpoints From PAPILLON
Lea Ruge, Enriqueta Felip, Catherine Shu, Andres Aguilar, Ke-Jing Tang, Maria Del Rosario Garcia Campelo, Kang-yun Lee, Angelo Delmonte, Joshua K. Sabari, Nicolas Girard, Aaron S. Mansfield, Keunchil Park, Caicun Zhou, Karen Xia, Archan Bhattacharya, Mark Wade, Mahadi Baig, Trishala Agrawal, Parthiv Mahadevia, Roland E. Knoblauch, Rachel E. Sanborn
Amivantamab Plus Chemotherapy vs Chemotherapy in EGFR-mutant Advanced NSCLC After Progression on Osimertinib: A Post-progression Analysis of MARIPOSA-2
Amanda Tufman, Ryan D. Gentzler, Alexander I. Spira, Barbara Melosky, Scott Owen, Timothy F. Burns, Erminia Massarelli, Misako Nagasaka, Bruno Fang, Rachel E. Sanborn, Oscar Arrieta, Cynthia Card, Federico Cappuzzo, Karen Xia, Pei-Ling Chu, Sujay Shah, Brooke Diorio, Angela Girvin, Parthiv Mahadevia, Joshua M. Bauml, Karen L. Reckamp
Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Subgroup Analysis by Cytogenetic Risk
Hermann Einsele, Roberto Mina, Binod Dhakal, Jesús San-Miguel, Mi Kwon, Duncan Purtill, Hila Magen, Magdalena Dutka, Michel Delforge, Ravi Vij, Stina Wichert, Sung-Soo Yoon, Monique C. Minnema, Nikoletta Lendvai, Carolina Lonardi, Ana Slaughter, Martin Vogel, Katherine Li, Diana Chen, Man Zhao, Tzu-min Yeh, Nina Benachour, Tamar Lengil, Mythili Koneru, Nitin Patel, Erika Florendo, Octavio Costa Filho, Salomon Manier, Joaquin Martinez-Lopez
Ciltacabtagene Autoleucel vs Standard of Care in Patients With Functional High-Risk Multiple Myeloma: CARTITUDE-4 Subgroup Analysis
Katja Weisel, Luciano J. Costa, Niels W.C.J. van de Donk, Surbhi Sidana, Yaël C. Cohen, Duncan Purtill, Cyrille Touzeau, Carlos Fernández de Larrea, Joaquin Martinez-Lopez, Nikoletta Lendvai, Ana Slaughter, Carolina Lonardi, Man Zhao, Katherine Li, Martin Vogel, Mythili Koneru, Nitin Patel, Erika Florendo, Octavio Costa Filho, María-Victoria Mateos
Comparative Effectiveness of Ciltacabtagene Autoleucel From the CARTITUDE-4 Trial vs Real-World Physician's Choice of Therapy From the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma
Katja Weisel, Luciano J. Costa, Niels W.C.J. van de Donk, Surbhi Sidana, Yaël C. Cohen, Duncan Purtill, Cyrille Touzeau, Carlos Fernández de Larrea, Joaquin Martinez-Lopez, Nikoletta Lendvai, Ana Slaughter, Carolina Lonardi, Man Zhao, Katherine Li, Martin Vogel, Mythili Koneru, Nitin Patel, Erika Florendo, Octavio Costa Filho, María-Victoria Mateos
Daratumumab (DARA) + Bortezomib/Lenalidomide/Dexamethasone (VRd) in Transplant-Eligible (TE) Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the PERSEUS Trial
Hermann Einsele, Paula Rodriguez-Otero, Philippe Moreau, Meletios A. Dimopoulos, Meral Beksac, Aurore Perrot, Annemiek Broijl, Francesca Gay, Roberto Mina, Niels W.C.J. van de Donk, Fredrik Schjesvold, Michel Delforge, Andrew Spencer, Sarah Lonergan, Diego Vieyra, Anna Sitthi-Amorn, Robin Carson, Joan Bladé Mario Boccadoro, Pieter Sonneveld
Daratumumab (DARA)/Bortezomib/Lenalidomide/Dexamethasone (D-VRd) With D-R Maintenance (Maint) In Transplant-eligible (TE) Newly Diagnosed Myeloma (NDMM): Analysis of PERSEUS Based on Cytogenic Risk
Christoph Driessen, Meletios A. Dimopoulos, Pieter Sonneveld, Paula Rodriguez-Otero, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W.C.J. van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda Balari, Laura Rosiñol, Michel Delforge, Wilfried Roeloffzen, Annette Vangsted, Hermann Einsele, Andrew Spencer, Roman Hajek, Artur Jurczyszyn, Sarah Lonergan, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M.J. van Brummelen, Veronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Joan Bladé, Mario Boccadoro, Philippe Moreau
Effect of Amivantamab Dose Interruptions on Efficacy and Safety of First-line Amivantamab Plus Lazertinib in EGFR-mutant Advanced NSCLC: Exploratory Analyses From the MARIPOSA study
Johannes Schnorbach, Maria del Rosario Garcia Campelo, Byoung Chul Cho, Nicolas Girard, Shun Lu, Hiroshige Yoshioka, Jong-Seok Lee, Se-Hoon Lee, Baogang Liu, Mehmet Ali Sendur, Benjamin Besse, Alexander I. Spira, Enriqueta Felip, Andres Aguilar, Joshua K. Sabari, Sanjay Popat, Karen Xia, Parthiv Mahadevia, Seema Sethi, Joshua M. Bauml, Yuriy Ostapenko
Efficacy and Safety in Patients With Lenalidomide-Refractory Multiple Myeloma and 1–3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 CARTITUDE-4 Trial
Hermann Einsele, M. Hasib Sidiqi, Paolo Corradini, Duncan Purtill, Binod Dhakal, Lionel Karlin, Salomon Manier, Shinsuke Iida, Sebastian Giebel, Simon J. Harrison, Brea Lipe, Abdullah M. Khan, Jordan M. Schecter, Carolyn C. Jackson, Tzu-min Yeh, Arnob Banerjee, William Deraedt, Nikoletta Lendvai, Carolina Lonardi, Ana Slaughter, Katherine Li, Diana Chen, Jane Gilbert, Tito Roccia, Man Zhao, Nitin Patel, Erika Florendo, Mythili Koneru, Octavio Costa Filho, Dong Geng, Jesús San-Miguel, Kwee Yong
Efficacy and Safety of Erdafitinib in Adults With Breast Cancer and Prespecified Fibroblast Growth Factor Receptor Alterations in the Phase 2 Open-label, Single-Arm RAGNAR Trial
Dirk Arnold, Omar Carranza, Martin Schuler, Josep Tabernero, Yohann Loriot, Gunnar Folprecht, Daniel Palmer, Graziela Z. Dal Molin, Martin Gutierrez, Hans Prenen, Iwona Lugowska, Andres Cervantes, Hussein Sweiti, Constance Hammond, Saltanat Najmi, Shibu Thomas, Spyros Triantos, Lauren Crow, Shubham Pant
Efficacy and Safety of Erdafitinib in Adults With NSCLC and Prespecified Fibroblast Growth Factor Receptor (FGFR) Alterations in the Phase 2 Open-label, Single-Arm RAGNAR Trial
Martin Schuler, Josep Tabernero, Omar Carranza, Yohann Loriot, Shubham Pant, Dirk Arnold, Gunnar Folprecht, Daniel Palmer, Hans Prenen, Graziela Z. Dal Molin, Iwona Ługowska, Andrés Cervantes, Hussein Sweiti, Constance Hammond, Saltanat Najmi, Shibu Thomas, Spyros Triantos, Karen Xia, Martin Gutierrez
View presentation (German)
Efficacy and Safety of Erdafitinib in Patients With Advanced or Metastatic Cholangiocarcinoma and FGFR Alterations: Pooled Analysis of RAGNAR and LUC2001 Studies
Gunnar Folprecht, Shubham Pant, Joon Oh Park, Wu-Chou Su, Martin Schuler, Yohann Loriot, Gopa Iyer, Toshihiko Doi, Shukui Qin, Josep Tabernero, Hans Prenen, Helen Winter, Graziela Z. Dal Molin, Hussein Sweiti, Saltanat Najmi, Constance Hammond, Huimin Liao, Shibu Thomas, Spyros Triantos, Yin-Hsun Feng
Final Survival Analysis of Daratumumab Plus Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (NDMM): MAIA Study
Hartmut Goldschmidt, Thierry Facon, Shaji K. Kumar, Robert Z. Orlowski, Nizar Bahlis, Philippe Moreau, Supratik Basu, Cyrille Hulin, Sonja Zweegman, Katja Weisel, Aurore Perrot, Caroline Jacquet, Noopur Raje, Salomon Manier, Ajai Chari, Markus Hansson, Mohamad Mohty, Michel Delforge, Torben Plesner, Gordon Cook, Xavier Leleu, Hang Quach, Christopher P. Venner, Mourad Tiab, Margaret Macro, Laurent Frenzel, George Wang, Huiling Pei, Kasey Bolyard, Robin Carson, Fredrik Borgsten, Saad Z. Usmani
Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
Leo Rasche, Carolina Schinke, Cyrille Touzeau, Monique C. Minnema, Niels W.C.J. van de Donk, Paula Rodríguez-Otero, María-Victoria Mateos, Jing Christine Ye, Deeksha Vishwamitra, Indrajeet Singh, Xiang Qin, Michela Campagna, Tara Masterson, Brandi W. Hilder, Jaszianne Tolbert, Thomas Renaud, Christoph Heuck, Colleen Kane, Ajai Chari
Long-Term Follow-up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma
Britta Besemer, Alfred L. Garfall, Ajay K. Nooka, Niels W.C.J. van de Donk, Philippe Moreau, Manisha Bhutani, Albert Oriol, Thomas G. Martin, Laura Rosiñol, María-Victoria Mateos, Nizar Bahlis, Rakesh Popat, Joaquin Martinez-Lopez, Amrita Krishnan, Michel Delforge, Lin Huang, Deeksha Vishwamitra, Tara Stephenson, Katherine Chastain, Surbhi Sidana
Real-Life Outcomes in Patients With BCMA-Exposed Relapsed/Refractory Multiple Myeloma Treated With Standard of Care in the LocoMMotion and MoMMent Studies
Katja Weisel, Britta Besemer, Salomon Manier, Hartmut Goldschmidt, Niels W.C.J. van de Donk, Hermann Einsele, Aurore Perrot, Raphael Teipel, Lionel Karlin, Christof Scheid, Charlotte Pawlyn, Joaquín Martínez López, Michele Cavo, Claire Albrecht, Lorenzo Acciarri, Imène Haddad, Vadim Strulev, Kathleen Gray, Margaret Doyle, Philippe Moreau, María-Victoria Mateos
The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients With Multiple Myeloma and 1–3 Prior Lines of Therapy (Cohort A) and With Early Relapse After First Line Treatment (Cohort B)
Marc-Steffen Raab, Jens Hillengass, Adam D. Cohen, Mounzer Agha, Michel Delforge, Tessa Kerre, Wilfried Roeloffzen, Hermann Einsele, Hartmut Goldschmidt, Katja Weisel, Christof Scheid, Sébastien Anguille, Pieter Sonneveld, Sonja Zweegman, Jordan M. Schecter, Kevin C. De Braganca, Carolyn C. Jackson, Philip Vlummens, Helen Varsos, Christina Corsale, Deepu Madduri, Tzu-min Yeh, Pankaj Mistry, Tito Roccia, Qingxuan Song, Muhammad Akram, Octavio Costa Filho, Dong Geng, Yaël C. Cohen, Niels W.C.J. van de Donk
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.